Therefore, inhibition of glutaminolysis with different glutaminase inhibitors (BPTES, CB-839) has shown higher in vitro anti-leukemic activities in IDH mutant cells than in IDH wild-type cells [28, 114], in line with the results obtained in gliomas [163]. Here, IDH1 is linked to central nervous system cancer.